Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical featuresOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut and lung microbiota differ between benign and malignant lung masses, and whether they can predict lung cancer. Researchers sequenced the 16S rRNA gene in stool and bronchoalveolar lavage fluid (BALF). They compared bacterial composition across the two body sites and linked it to clinical features. Diagnostic models were built with a random forest classifier and with differential taxa, then scored by ROC analysis.
Who was studied?
The cohort was patients evaluated for lung masses at Zhongshan Hospital, Fudan University, in Shanghai, China, enrolled between January and May 2020. This was a human observational study using 16S rRNA sequencing. The fecal group had 238 samples: 190 lung cancer and 48 benign lesions. The BALF group had 34 samples: 26 lung cancer and 8 benign. Cancers included non-small-cell (NSCLC) and small-cell (SCLC) subtypes.
What were the most important findings?
Alpha and beta diversity did not differ significantly between benign and malignant masses at either site. In stool, Lachnospiraceae_NK4A136_group (p=0.003232) and Erysipelotrichaceae_UCG-003 (p=0.01316) rose in cancer. In lavage fluid, Proteobacteria increased in cancer (p=0.03654), while Firmicutes was higher in benign masses. Bacteroides was enriched in NSCLC versus SCLC in stool. A lavage combination of Megasphaera and Saccharibacteria reached an AUC of 0.8 (95% CI 0.59-1) for malignancy.
What are the greatest implications of this study?
The findings suggest lung-lavage microbiota may be a more reliable marker than gut microbiota for classifying lung masses. This could complement imaging and biopsy in early diagnosis. The near-absence of shared signals between sites argues against microbial migration along the gut-lung axis. The BALF sample size was small (n=34), so these predictive results need validation in larger prospective cohorts.